-

Tempus to Participate in Morgan Stanley’s 23rd Annual Global Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in Morgan Stanley’s 23rd Annual Global Healthcare Conference. The conference will take place September 8-10 in New York City. Eric Lefkofsky, Founder and CEO of Tempus, and Jim Rogers, Chief Financial Officer, will participate in a fireside chat on September 8 from 1:05 to 1:40 p.m. EST.

A live audio webcast of the conversation will be available here.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Contacts

Hanah Heintzelman
hanah.heintzelman@tempus.com

Tempus AI, Inc.

NASDAQ:TEM

Release Versions

Contacts

Hanah Heintzelman
hanah.heintzelman@tempus.com

More News From Tempus AI, Inc.

Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of its new HRD-RNA algorithm. This next-generation model represents a significant improvement in identifying Homologous Recombination Deficiency (HRD), providing a more robust, functional assessment of tumor biology compared to traditional static DNA-based assays. Tempus HRD-RNA is an AI-driven, 1,660-gene logistic regression model de...

Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a collaboration with Median Technologies (EPA: ALMDT) to bring Median’s proprietary eyonis® LCS to the Tempus Pixel platform. This collaboration empowers clinical workflows with a powerful tool to support informed diagnostic and disease management decisions. According to a study by the American Cancer Society, only about 20% of eligible individu...

Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus’ Investor Rel...
Back to Newsroom